Ownership signal CIK-linked ownership evidence from parsed SEC filings. 1 signal
Large-stake signal

Form

SCHEDULE 13G/A

Passive or exempt beneficial ownership filing.

Ownership

2%

Beneficial ownership of this reported class.

Event date

31 Dec 2024

Date tied to the ownership event or amendment.

Accepted by SEC

14 Feb 2025

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Subject security Names, identifiers, and filing context for this profile. 1 source field
Symbol
ANAB
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
SCHEDULE 13G/A
Accepted by SEC
14 Feb 2025, 11:25:36 UTC
Event date
31 Dec 2024
Next SEC filing
14 Feb 2025
Source filing
View source filing
Filing notes and source

Key filing fact

Frazier Life Sciences Public Fund, L.P. disclosed 2% ownership in AnaptysBio, Inc. Common Stock (ANAB) on 31 Dec 2024.

Key facts

  • Frazier Life Sciences Public Fund, L.P. filed SCHEDULE 13G/A for AnaptysBio, Inc. Common Stock (ANAB).
  • Disclosed ownership: 2%.
  • Date of event: 31 Dec 2024.

Change

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 14 Feb 2025, 11:25.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

View source filing

Reporting persons

Disclosed reporting parties (25)

Names, ownership percentages, voting power, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power CIK
Frazier Life Sciences Public Fund, L.P. 2% 0 612,503
FHMLSP, L.P. 2% 612,503 0 612,503
FHMLSP, L.L.C. 2% 612,503 0 612,503
Frazier Life Sciences Public Overage Fund, L.P. 0.3% 77,778 0 77,778
FHMLSP Overage, L.P. 0.3% 77,778 0 77,778
FHMLSP Overage, L.L.C. 0.3% 77,778 0 77,778
Frazier Life Sciences X, L.P. 0.3% 77,014 0 77,014
FHMLS X, L.P. 0.3% 77,014 0 77,014
FHMLS X, L.L.C. 0.3% 77,014 0 77,014
Frazier Life Sciences XI, L.P. 0.5% 165,521 0 165,521
FHMLS XI, L.P. 0.5% 165,521 0 165,521
FHMLS XI, L.L.C. 0.5% 165,521 0 165,521
Frazier Healthcare VII, L.P. 1.6% 498,769 0 498,769
Frazier Healthcare VII-A, L.P. 0.5% 142,134 0 142,134
FHM VII, L.P. 2.1% 640,903 0 640,903
FHM VII, L.L.C. 2.1% 640,903 0 640,903
James N. Topper 5.4% 1,655,295 80,812 1,574,483
Patrick J. Heron 5.2% 1,583,593 9,110 1,574,483
Albert Cha 2.3% 690,281 0 690,281
James Brush 2.3% 690,281 0 690,281
Daniel Estes 0.5% 165,521 0 165,521
Alan Frazier 2.1% 640,903 0 640,903
Nader Naini 2.1% 640,903 0 640,903
Nathan Every 2.1% 645,526 4,623 640,903
Brian Morfitt 2.1% 646,272 5,369 640,903
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .